Dynamic monitoring of carcinoembryonic antigen, CA19-9 and inflammation-based indices in patients with advanced colorectal cancer undergoing chemotherapy

Table 2 Carcinoembryonic antigen and carbohydrate antigen and inflammatory index characteristics at baseline and at the 1^st and 2^nd evaluations

Markers	Baseline	1st evaluation	2nd evaluation
CEA1	6.99 (2.50-61.46)	5.86 (1.88-29.43)	6.53 (1.55-36.02)
CA19-91	2.68 (1.1-23.58)	2.76 (0.91-9.21)	3.13 (0.76-11.86)
NLR	2.22 (1.60-3.64)	1.77 (1.18-2.65)	2.19 (1.43-3.17)
PLR	144.87 (93.64-213.97)	115.43 (82.78-170.98)	141.19 (92.82-187.82)
LMR	3.92 (2.56-5.58)	4.21 (2.62-5.43)	3.56 (2.62-5.00)
SII	614.89 (298.31-1219.48)	339.34 (227.13-570.24)	475.02 (238.59-858.52)

¹Values are expressed as × upper normal limit for carcinoembryonic antigen and carbohydrate antigen, not as the absolute value; the neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, lymphocyte-to-monocyte ratio and systemic immune-inflammation index calculated as the absolute value × 10⁹/L. Data are presented as median (interquartile range). CEA: Carcinoembryonic antigen; CA19-9: Carbohydrate antigen; NLR: Neutrophil-to-lymphocyte ratio; PLR: Platelet-to-lymphocyte ratio; LMR: Lymphocyte-to-monocyte ratio; SII: Systemic immune-inflammation index.